Author(s): Anny Setijo Rahaju, Arifa Mustika, Priangga Adi Wiratama, Lukman Hakim, Doddy M. Soebadi


DOI: 10.52711/0974-360X.2023.00214   

Address: Anny Setijo Rahaju1,2,3,4*, Arifa Mustika5, Priangga Adi Wiratama2,4, Lukman Hakim3,4,6, Doddy M. Soebadi4,6
1Doctoral Program in Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
2Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
3Universitas Airlangga Teaching Hospital, Surabaya, Indonesia.
4Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
5Divison Pharmacology and Therapy, Department of Anatomy, Histology, and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
6Department of Urology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
*Corresponding Author

Published In:   Volume - 16,      Issue - 3,     Year - 2023

Bladder cancer is considered as one of the main drivers of cancer related mortality in adult men. Data from Global Cancer Statistics 2018 (GLOBOCAN) showed that the bladder cancer was included among the Top 10 cancer incidence in worldwide. Meanwhile, metformin, an antidiabetic agent, is believed to be able to impede the varying cancer cells expansion. Many examinations had displayed that metformin interferes via the AMPK/mTOR axis pathway, thereby suppressing tumor growth. AMPK activation can also increase stromal cell survival through p53 activation. Metformin also disrupts the cell cycle by decreasing the cyclin D1 protein in cancer cells. The human cell line 5637 was treated with metformin 15 mM, examined for cyclin D1 and p53 by immunohistochemical staining and assessed for the viability of cancer cells. The Statistic test was utilized to make a comparison of tumor viabilities and other variables. No significant differences were found in the expression of wild type p53 and cyclin D1 but significant differences were observed in the viability between the control and metformin groups. We have proven in our study that the anti-tumor effect of metformin in reducing the viability of urothelial carcinoma tumor cells not only through p53 and cyclin D1.

Cite this article:
Anny Setijo Rahaju, Arifa Mustika, Priangga Adi Wiratama, Lukman Hakim, Doddy M. Soebadi. Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma. Research Journal of Pharmacy and Technology 2023; 16(3):1303-8. doi: 10.52711/0974-360X.2023.00214

Anny Setijo Rahaju, Arifa Mustika, Priangga Adi Wiratama, Lukman Hakim, Doddy M. Soebadi. Antitumor activity of Metformin through p53 and Cyclin D1 in the Urothelial Cell Carcinoma. Research Journal of Pharmacy and Technology 2023; 16(3):1303-8. doi: 10.52711/0974-360X.2023.00214   Available on:

1.    Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953.
2.    Zhang T, Guo P, Zhang Y, et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci. 2013;14(12):24603-24618.
3.    Rahaju AS, Mustika A, Wiratama PA, et al. Correlation Between VEGF and EGFR Expression in Urothelial Carcinoma of Bladder. J Int Dent Med Res ISSN 1309-100X. 2021;14(2):849-854.
4.    Antonius Y, Utomo DH, Widodo. Identification of potential biomarkers in nasopharyngeal carcinoma based on protein interaction analysis. International Journal of Bioinformatics Research and Applications. 2017; 13(4): 376-88.
5.    Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66(21):10269-10273.
6.    Anisimov VN, Berstein LM, Egormin PA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005;40(8-9):685-693.
7.    Rattan R, Giri S, Hartmann LC, Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011;15(1):166-178.
8.    Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in Vivo. Neoplasia. 2011;13(5):483-491.
9.    Sahra I Ben, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-3586.
10.    Kato K, Iwama H, Yamashita T, et al. The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep. 2016;35(3):1582-1592.
11.    Ben Sahra I, Le Marchand-Brustel Y, Tanti J-F, Bost F. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? Mol Cancer Ther. 2010;9(5):1092-1099.
12.    Widyananda MH, Pratama SK, Samoedra RS, Sari FN, Kharisma VD, Ansori ANM. Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins. J Pharm Pharmacogn Res. 2021; 9(4): 484-496.
13.    Zheng Q you, Jin F suo, Yao C, Zhang T, Zhang G hui, Ai X. Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Biophys Res Commun. 2012;419(4):741-747.
14.    Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67(14):6745-6752.
15.    Proboningrat A, Kharisma VD, Ansori ANM, Rinza Rahmawati, Amaq Fadholly, Gabrielle Ann Villar Posa, Sri Agus Sudjarwo, Fedik Abdul Rantam, Agung Budianto Achmad. In silico Study of Natural inhibitors for Human papillomavirus-18 E6 protein. Research Journal of Pharmacy and Technology. 2022; 15(3):1251-6. doi: 10.52711/0974-360X.2022.00209
16.    Yi Y, Zhang W, Yi J, Xiao Z-X. Role of p53 Family Proteins in Metformin Anti-Cancer Activities. J Cancer. 2019;10(11):2434-2442.
17.    Fadholly A, Ansori ANM, Jayanti S, Proboningrat A, Muhammad K. J. Kusala, Naimah Putri, Fedik A. Rantam, Sri A. Sudjarwo. Cytotoxic Effect of Allium cepa L. Extract on Human colon Cancer (WiDr) Cells: In Vitro Study. doi: 10.5958/0974-360X.2019.00591.2
18.    Hadad SM, Hardie DG, Appleyard V, Thompson AM. Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. 2014;16(8):746-752.
19.    Zhuang Y, Keith WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008;3:1-11.
20.    Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):1-11.
21.    Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling. Oncol Res. 2011;19(6):275-285.
22.    Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, et al. In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol. 2011;668(3):373-382.
23.    Fadholly A, Ansori ANM, Sucipto TH. An Overview of Naringin: Potential Anticancer compound of Citrus Fruits. Research J. Pharm. and Tech. 2020; 13(11):5613-5619. doi: 10.5958/0974-360X.2020.00979.8
24.    Yi G, He Z, Zhou X, et al. PhenoLow concentration of metformin induces a p53-dependent senescence in hepatoma cells via activation of the AMPK pathway. Int J Oncol. 2013;43(5):1503-1510.
25.    Jeong YK, Kim MS, Lee JY, Kim EH, Ha H. Metformin radiosensitizes p53-deficient colorectal cancer cells through induction of G2/M arrest and inhibition of DNA repair proteins. PLoS One. 2015;10(11):1-15.
26.    Proboningrat A, Jayanti S, Fadholly A, Ansori ANM, Naimah Putri, Muhammad K. J. Kusala, Sri A. Sudjarwo, Fedik A. Rantam, Agung Budianto Achmad. The Cytotoxicity of Ethanolic Extract of Allium cepa L. on Hela Cell Lines. Research Journal of Pharmacy and Technology. 2021; 14(9):4969-2. doi: 10.52711/0974-360X.2021.00864
27.    Hartog H, Wesseling J, Boezen HM, van der Graaf WTA. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur J Cancer. 2007;43(13):1895-1904.
28.    Fadholly A, Ansori ANM, Utomo B. Anticancer Effect of Naringin on Human Colon Cancer (WiDr Cells): In Vitro Study. Research Journal of Pharmacy and Technology. 2022; 15(2):885-8. doi: 10.52711/0974-360X.2022.00148
29.    Proboningrat A, Ansori ANM, Fadholly A, Naimah Putri, Muhammad Khaliim Jati Kusala, Agung Budianto Achmad. First Report on the Cytotoxicity of Pinus merkusii Bark Extract in WiDr, A Human Colon Carcinoma Cell Line. Research J. Pharm. and Tech 2021; 14(3):1685-1688. doi: 10.5958/0974-360X.2021.00299.7
30.    Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
31.    Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene. 2007;26(11):1636-1644.
32.    Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2002;1(4):339-353.
33.    Nayak SK, Khatik GL, Rakesh Narang, Vikramdeep Monga. Role of Mdm2 Cascade in Human Cancers. Research J. Pharm. and Tech. 2017; 10(7): 2236-2242. DOI: 10.5958/0974-360X.2017.00396.1
34.    Wang CF, Zhang G, Zhao LJ, et al. Overexpression of the Insulin Receptor Isoform A Promotes Endometrial Carcinoma Cell Growth. PLoS One. 2013;8(8):1-10.
35.    Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res. 2010;3(9):1066-1076.
36.    Malaguarnera R, Sacco A, Morcavallo A, et al. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling. Endocrinology. 2014;155(4):1207-1221.
37.    Parveen A, Jough SS. Study on the Cytotoxic Impacts of Thymol as the Segment of Trachyspermum ammi on Bosom Disease (MCF-7) Cells. Asian J. Research Chem. 2020; 13(5):327-333. DOI: 10.5958/0974-4150.2020.00063.2
38.    Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat. 2010;123(1):271-279.
39.    Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between Insulin/IGF-1 and GPCR Signaling Systems: A Novel Target for the Anti-diabetic Drug Metformin in Pancreatic Cancer. Clin Cancer Res. 2010;16(9):2505-2511.
40.    Lei Y, Yi Y, Liu Y, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017;36(1):1-9.
41.    Yadav AR, Mohite SK. Anticancer Activity of Psidium guajava Leaf Extracts on Breast Cancer Cell Line. Res. J. Pharma. Dosage Forms and Tech.2020; 12(4):298-300. DOI: 10.5958/0975-4377.2020.00049.X
42.    Bhukya B, Lingabathula H, Narsimhareddy Yellu. Evaluation of Anti Cancer Activity of Kydia calycina Roxb. Leaf Extract on Different Cancer Cell Lines. Res. J. Pharmacognosy and Phytochem. 2017; 9(4): 197-202. DOI: 10.5958/0975-4385.2017.00036.X

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available